Key result
Mibefradil rapidly and selectively blocked T-type Ca2+ current in Y1 cells in a dose-dependent manner with a half maximum action at 10-7 M, being more effective at depolarized membrane potentials.
Why the study?
Does mibefradil block T-type Ca2+ currents in Y1 cells?
Does mibefradil block T-type Ca2+ currents in Y1 cells?
Mibefradil acts as a selective, dose-dependent T-type calcium channel blocker in Y1 cells, with enhanced efficacy at depolarized membrane potentials.
The effect of mibefradil, a new nondihydropyridine Ca2+ channel antagonist, was investigated on Y1 cells which exhibited T-and L-type Ca2+ currents. In the great majority of these cells, mibefradil rapidly and selectively blocked T-type Ca2+ current in a dose-dependent manner with a half maximum action at 10-7 M. Furthermore, the specific L-type Ca2+ channel inhibitor, nifedipine, blocked the Ca2+ inward current remaining after the action of mibefradil. Mibefradil does not modify the voltage-dependent characteristics of the current/voltage relationship. However, mibefradil is more effective at depolarized membrane potential.
No takes yet. Share an insight, caveat, or question.
Esneu et al. (1998) studied Y1 cells exhibiting T- and L-type Ca2+ currents. Mibefradil was evaluated on T-type Ca2+ current block. Mibefradil rapidly and selectively blocked T-type Ca2+ current in Y1 cells in a dose-dependent manner with a half maximum action at 10-7 M, being more effective at depolarized membrane potentials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: